MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Bayer

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
U.S. FDA Accepts Supplemental New Drug Application Under Priority Review for New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
From Bayer
Via Business Wire
News headline image
Bayer Introduces Vyconic™ Soybeans, a Groundbreaking Advance in Weed Management, at Commodity Classic 2025
From Bayer
Via Business Wire
News headline image
Late-breaking data from QUANTI CNS (Central Nervous System) presented at ECR 2025:
From Bayer
Via Business Wire
News headline image
Bayer® Aspirin Continues Longstanding Commitment to Heart Health Education, Encouraging Americans to “See Their Risks”
From Bayer
Via Business Wire
News headline image
New Data for NUBEQA® Build on Safety and Efficacy Results Across Subgroups of Patients with Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer Unveils Latest Data from Prostate Cancer Portfolio at 2025 ASCO GU Cancers Symposium
From Bayer
Via Business Wire
News headline image
Leaps by Bayer Announces One of the Largest Global Surveys of Society’s Attitudes Toward Breakthrough Technologies
From Bayer
Via Business Wire
News headline image
New U.S. Survey Conducted On Behalf Of One A Day® by Bayer Highlights Four in Five GenZ Women Feel Societal Pressures Impact Their New Year’s Resolutions
From Bayer
Via Business Wire
News headline image
Bayer’s Pharma Growth Strategy Progressing Well as Pipeline Advances
From Bayer
Via Business Wire
News headline image
Bayer’s investigational MRI contrast agent gadoquatrane meets primary and main secondary endpoints in pivotal Phase III studies
From Bayer
Via Business Wire
News headline image
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking New Indication for KERENDIA® (finerenone) in Patients with Heart Failure with Left Ventricular Ejection Fraction of ≥40%
From Bayer
Via Business Wire
News headline image
Elinzanetant Meets All Primary and Secondary Endpoints in Phase III Study OASIS 4 for Treatment of Moderate to Severe Vasomotor Symptoms Caused by Breast Cancer Treatments
From Bayer
Via Business Wire
News headline image
Bayer: Federal Court Brings an End to Roundup™ Litigation in Australia
From Bayer
Via Business Wire
News headline image
Bayer Partners with America’s Grow-A-Row to Aid in the Fight Against Hunger in New Jersey
From Bayer
Via Business Wire
News headline image
Bayer Showcases Growing Radiology Portfolio at RSNA 2024
From Bayer
Via Business Wire
News headline image
Bayer Announces ‘Project Enhanced S3’ to Enable Companies to Realize Additional Sustainability Value from Carbon Removal Projects
From Bayer
Via Business Wire
News headline image
U.S. FDA Accepts Supplemental New Drug Application for NUBEQA® (darolutamide) for the Treatment of Patients with Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer to Present New Prespecified Subgroup Analyses from Investigational Phase III FINEARTS-HF Trial in Patients with Heart Failure with LVEF ≥40% at AHA 2024
From Bayer
Via Business Wire
News headline image
Bayer’s Receives FDA Clearance for MEDRAD® Centargo CT Injection System
From Bayer
Via Business Wire
News headline image
Bayer and Liveo Research Launch First-of-its-Kind Blister Packaging with Improved Environmental Footprint
From Bayer
Via Business Wire
News headline image
U.S. Food and Drug Administration (FDA) accepts New Drug Application for elinzanetant
From Bayer
Via Business Wire
News headline image
Bayer and MOMA Therapeutics Enter Collaboration and License Agreement in Oncology
From Bayer
Via Business Wire
News headline image
BlueRock Therapeutics’ Investigational Cell Therapy Bemdaneprocel for Parkinson’s Disease Shows Positive Data at 24-Months
From Bayer
Via Business Wire
News headline image
Bayer Submits Supplemental New Drug Application to U.S. FDA Seeking Expanded Indication for NUBEQA® (darolutamide) in Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
New Publication Evaluates Awareness of High Breast Density as a Risk Factor for Breast Cancer
From Bayer
Via Business Wire
News headline image
Bayer, UPMC Magee-Women’s Hospital, PA Senate President Pro Tempore Kim Ward Collaborate to Bring Breast Health Care and Awareness to Pittsburgh Region’s Rural and Underserved Communities
From Bayer
Via Business Wire
News headline image
ESMO 2024 Late-Breaking Data: Phase III ARANOTE Trial Shows NUBEQA® (darolutamide) Significantly Reduced Risk of Radiological Progression or Death in Metastatic Hormone-Sensitive Prostate Cancer
From Bayer
Via Business Wire
News headline image
Bayer Consumer Health Welcomes Bayer 04 Leverkusen to Kick Off Historic Trophy Tour in the U.S. After Undefeated Bundesliga Season
From Bayer
Via Business Wire
News headline image
Welcome to “Wita”: Claritin® Aims to Take the ‘Itch’ Out of Wichita, the #1 Allergy Capital in the U.S., Just in Time for Fall Allergy Season
From Bayer
Via Business Wire
News headline image
Data from Phase III study OASIS 3 support efficacy and long-term safety of investigational compound elinzanetant in the treatment of moderate to severe vasomotor symptoms associated with menopause
From Bayer
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story